GlaxoSmithKline leans on respiratory franchise with Trelegy share-grab

30th October 2019 Uncategorised 0

GlaxoSmithKline has said for years that the newer members of its respiratory franchise would step up to replace sales for blockbuster Advair when generics finally hit the scene. And thanks to a market-share grab for triple-drug COPD therapy Trelegy Ellipta, that strategy is working as planned.

More: GlaxoSmithKline leans on respiratory franchise with Trelegy share-grab
Source: fierce